ATE43497T1 - Pharmazeutische formulierung mit gesteuerter absorption. - Google Patents

Pharmazeutische formulierung mit gesteuerter absorption.

Info

Publication number
ATE43497T1
ATE43497T1 AT84308982T AT84308982T ATE43497T1 AT E43497 T1 ATE43497 T1 AT E43497T1 AT 84308982 T AT84308982 T AT 84308982T AT 84308982 T AT84308982 T AT 84308982T AT E43497 T1 ATE43497 T1 AT E43497T1
Authority
AT
Austria
Prior art keywords
methyldopa
total
pharmaceutical formulation
controlled absorption
pellet
Prior art date
Application number
AT84308982T
Other languages
English (en)
Inventor
Donald Eugene Panoz
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE43497T1 publication Critical patent/ATE43497T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
AT84308982T 1983-12-21 1984-12-20 Pharmazeutische formulierung mit gesteuerter absorption. ATE43497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE3026/83A IE56459B1 (en) 1983-12-21 1983-12-21 Controlled absorption pharmaceutical formulation
EP84308982A EP0156077B1 (de) 1983-12-21 1984-12-20 Pharmazeutische Formulierung mit gesteuerter Absorption

Publications (1)

Publication Number Publication Date
ATE43497T1 true ATE43497T1 (de) 1989-06-15

Family

ID=11037484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84308982T ATE43497T1 (de) 1983-12-21 1984-12-20 Pharmazeutische formulierung mit gesteuerter absorption.

Country Status (9)

Country Link
US (1) US4716040A (de)
EP (1) EP0156077B1 (de)
JP (1) JPS60156612A (de)
AT (1) ATE43497T1 (de)
BE (1) BE901328A (de)
CH (1) CH662506A5 (de)
DE (1) DE3478396D1 (de)
IE (1) IE56459B1 (de)
PH (1) PH20628A (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DE69201793T2 (de) * 1991-05-20 1995-09-21 Marion Laboratories Inc Mehrschichtige zubereitung mit kontrollierter freisetzung.
JP2535141B2 (ja) * 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20090214643A1 (en) * 2005-07-19 2009-08-27 Franklin Amie E Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
WO2007090091A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
KR101413613B1 (ko) * 2006-01-27 2014-07-10 앱탈리스 파마테크, 인코포레이티드 약 염기성 선택성 세로토닌 5-ht3 차단제와 유기산을 포함하는 약물 전달 시스템
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
JPS5414649A (en) * 1977-07-06 1979-02-03 Hitachi Ltd Multi-level output circuit
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
IT1168014B (it) * 1981-08-05 1987-05-20 Erba Farmitalia Forme farmaceutiche a cessione protratta
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms

Also Published As

Publication number Publication date
EP0156077B1 (de) 1989-05-31
US4716040A (en) 1987-12-29
CH662506A5 (fr) 1987-10-15
EP0156077A1 (de) 1985-10-02
PH20628A (en) 1987-03-06
BE901328A (fr) 1985-04-16
IE833026L (en) 1985-06-21
IE56459B1 (en) 1991-08-14
JPS60156612A (ja) 1985-08-16
DE3478396D1 (en) 1989-07-06

Similar Documents

Publication Publication Date Title
ATE43497T1 (de) Pharmazeutische formulierung mit gesteuerter absorption.
ATE66813T1 (de) Arzneimittel-formulierung.
ATE53176T1 (de) Pharmazeutische zusammensetzung mit verzoegerter abgabe.
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ATE107857T1 (de) Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
NO162103C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
DE69100991D1 (de) Pharmazeutische formulierungen.
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
IT8220758A1 (it) Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
DE3856555D1 (de) Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
JPS5441320A (en) Slow release preparation and its manufacturing
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee